Patients with hematologic malignancies have many reasons to die during extracorporeal membrane oxygenation

Critical Care, Sep 2014

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

Patients with hematologic malignancies have many reasons to die during extracorporeal membrane oxygenation

Matthieu Schmidt 0 1 Daniel Brodie 0 1 Alain Combes 0 1 0 Medical-Surgical Intensive Care Unit, iCAN, Institute of Cardiometabolism and Nutrition, Hopital de la Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris , Paris , France 1 Authors' response Philipp Wohlfarth, Thomas Staudinger and Peter Schellongowski We read with great interest the article by Wohlfarth and colleagues [1] regarding the use of extracorporeal membrane oxygenation (ECMO) in 14 adult patients with hematological malignancies. We would like to highlight two main points. First, the authors focused their report and their discussion on bleeding complications and anticoagulation management in this high-risk population. Although we concede that it is a serious concern in these patients, it is not the only one. ECMO support is associated with nosocomial infections [2,3]. Impairment of cellular immunity, cytopenia and chemotherapy (CT) may further increase the risks of infection and may dissuade clinicians from using ECMO in these patients. Developing new strategies that aim to limit nosocomial infections is crucial to improving outcomes in this population. ECMO in awake, non-intubated, spontanWe thank the authors for their thoughtful considerations. Eight of the ten cases of pneumonia leading to ECMO were hospital-acquired. However, the number of proven infections during the ICU stay was low. Of 110 cultures (broncho-alveolar lavage, blood, urine, catheters, stool, pleural/pericardial effusion, lung biopsies, wound swaps, cerebrospinal fluid), only 6 were positive (catheter-related infection, n = 5; urinary tract infection, n = 1). Reactivation of cytomegalovirus or herpes simplex virus occurred in one and three patients, respectively. All patients had received broad-spectrum antibiotics, eight of them plus antifungals. - eously breathing patients with acute respiratory distress syndrome, to avoid mechanical ventilation and its related adverse events, is a potentially promising application [4]. Thus, in our opinion, it would also be important to provide a thorough description of nosocomial infections that might have occurred in these 14 patients. Second, the authors reported that 5 of 14 patients initially received CT while receiving ECMO. The pharmacokinetics of many of the medications administered to patients receiving ECMO are complex [5] and, to date, there are very limited data to guide our daily practice. Therefore, clinicians must be aware that providing CT to patients receiving ECMO is a potential gamble, which risks worsening patient outcomes due to ineffective drug regimens. CT during ECMO should be restricted to those cases where postponing therapy is not an option. Even apart from ECMO, optimal timing, pharmacokinetics and, therefore, dosing of CT in patients with acute organ dysfunctions is largely unknown. Nevertheless, CT may be the only option if hematologic malignancies themselves cause organ dysfunction, especially in pulmonary involvement [6]. Nowadays, administration of CT is common practice in critically ill patients and affects every fourth ICU patient with hematologic malignancies in dedicated centers [7]. Importantly, CT does not negatively influence survival in large cohorts, even in cases of subsequent sepsis [7-9]. By clinical judgment, postponing CT was not an option in any of our five patients, of whom three are in complete remission after 13, 15 and 46 months. As a survival benefit of veno-venous ECMO still has to be proven in patients with acute respiratory failure, thorough case-by-case evaluation is absolutely essential. 2014 Schmidt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated. According to our findings, the risk of nosocomial infections or CT-related issues should not lead to general exclusion of patients with hematologic malignancies from ECMO. Further research is warranted. Competing interests MS declares that they have no competing interests. DB reports receiving research support from Maquet Cardiovascular, including travel expenses for research meetings, as well as anticipated support for upcoming studies and compensation paid to Columbia University for research consulting. He receives no direct compensation from Maquet. He is a member of the Medical Advisory Board for ALung Technologies. Compensation is paid to Columbia University; he receives no direct compensation from ALung Technologies. AC is the primary investigator of the EOLIA trial, NCT01470703, a randomized trial of VV-ECMO supported in part by MAQUET. AC has received honoraria for lectures by MAQUET. Acknowledgements Source of funding: MS was supported by The French Intensive Care Society (SRLF), the 'Fonds de dotation Recherche en Sant Respiratoire, 2012', the 'Collge des Enseignants de Ranimation Mdicale' and the 'Fonds dEtudes et de Recherche du Corps Mdical, Assistance publique-Hpitaux de Paris'.

This is a preview of a remote PDF:

Matthieu Schmidt, Daniel Brodie, Alain Combes. Patients with hematologic malignancies have many reasons to die during extracorporeal membrane oxygenation, Critical Care, 2014, 522, DOI: 10.1186/s13054-014-0522-0